AMPT

drugbox

---

width=150
IUPAC_name = 2-amino-3-(4-hydroxyphenyl)-2- methylpropanoic acid
CAS_number = 658-48-0
ATC_prefix=
ATC_suffix=
PubChem=3125
DrugBank=
C=10 | H=13 | N=1 | O=3
molecular_weight = 195.21512 g/mol
bioavailability =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_status =
routes_of_administration =

Alpha-methyl-p-tyrosine (AMPT) is a drug that temporarily reduces brain catecholamine activity by competitively inhibiting tyrosine hydroxylase.

It has been used in the treatment of pheochromocytoma.cite journal |author=Ankenman R, Salvatore MF |title=Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia |journal=J Neuropsychiatry Clin Neurosci |volume=19 |issue=1 |pages=65–9 |year=2007 |pmid=17308229 |doi=10.1176/appi.neuropsych.19.1.65 |url=]

ide effects

AMPT administration leads to a transient exacerbation of depressive symptoms in patients that have responded to catecholaminergic antidepressants. The mood changes induced by AMPT may be mediated by decreases in norepinephrine, while changes in selective attention and motivation may be mediated by dopamine.

Prolonged administration can have an impact upon the circadian rhythm.cite journal |author=Zimmermann RC, Krahn LE, Klee GG, Ditkoff EC, Ory SJ, Sauer MV |title=Prolonged inhibition of presynaptic catecholamine synthesis with alpha-methyl-para-tyrosine attenuates the circadian rhythm of human TSH secretion |journal=J. Soc. Gynecol. Investig. |volume=8 |issue=3 |pages=174–8 |year=2001 |pmid=11390253 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S1071557601001046]

Mechanism

It prevents the conversion of tyrosine to L-DOPA, the precursor to dopamine.

References

External links

* [http://www.clinicaltrials.gov/ct/show/NCT00082030?order=10] and [http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2004-M-0160.html] A Clinical Trial